Mentioned in ?
References in periodicals archive ?
Sunovion's track record of discovery, development and commercialization of important therapies has included Brovana (arformoterol tartrate), Latuda (lurasidone HCI), and most recently Aptiom (eslicarbazepine acetate).
Arformoterol is the single, (R,R)-isomer form of racemic formoterol, which is approved by the FDA as Brovana for maintenance treatment of COPD.
Including the two expected reissued patents, Dey believes that seven US patents are infringed by Sunovion's Brovana product.
Dey is currently pursuing a patent infringement lawsuit against Sepracor relating to its Brovana product."
Brovana, an inhaled drug launched last April for people with chronic obstructive pulmonary disease, brought in $6.3 million.
said its drug Brovana has received a specific billing code from the federal government's Centers for Medicare and Medicaid Services, a step in the new drug's market acceptance.
Sales of Brovana, a drug introduced in April for people with chronic obstructive pulmonary disease, hit $2.4 million.
Sepracor said in a filing with the Securities and Exchange Commission that Dey alleges Sepracor's Brovana drug infringes on Dey's single U.S.
Sepracor's next source of revenue is Brovana, an inhaled treatment for chronic obstructive pulmonary disease due to go on sale in mid-2007.